The utility of nutritional supportive care with an eicosapentaenoic acid (EPA (cas 10417-94-4))-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study

Add time:08/02/2019    Source:sciencedirect.com

SummaryBackground & aimsNeoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC.

We also recommend Trading Suppliers and Manufacturers of EPA (cas 10417-94-4). Pls Click Website Link as below: cas 10417-94-4 suppliers

Prev:DHA and EPA (cas 10417-94-4) nanoemulsions prEPA (cas 10417-94-4)red by the low-energy emulsification method: Process factors influencing droplet size and physicochemical stability
Next:Effects of Stanozolol (cas 10418-03-5) on apoptosis mechanisms and oxidative stress in rat cardiac tissue)